VORANIGO results

The FDA approval of VORANIGO was based on a clinical trial that tested how effective and safe it is to treat Grade 2 IDH-mutant astrocytoma and oligodendroglioma with VORANIGO.

Percentage of people in the clinical trial without disease progressiona

Percentage of people without disease progression, VORANIGO vs placebo, Chart

aThe median follow-up duration was 14 months with VORANIGO and 14.3 months with placebo.

VORANIGO has been shown to increase the length of time a person can live with Grade 2 IDH-mutant astrocytoma or oligodendroglioma without it getting worse.

At the time the data was analyzed, 72% of people who took VORANIGO did not see their disease progress compared to 46% of people who took placebo.

Percentage of people in the clinical trial without disease progressiona

Percentage of people without disease progression, VORANIGO vs placebo, Chart

aThe median follow-up duration was 14 months with VORANIGO and 14.3 months with placebo.

People who took VORANIGO experienced additional benefits.

VORANIGO increased the amount of time until a person needed their next treatment—such as chemotherapy, radiation, or another surgery—compared to placebo.

See how to take VORANIGO
Learn more

ServierONE Patient Support Services

ServierONE offers patients helpful resources and tools for navigating treatment, costs, and education throughout their journeys, including a VORANIGO copay program.

For more information:
OR OR
Call
1-800-813-5905
Monday-Friday, 8 AM to 8 PM ET
caret

What is VORANIGO?

VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you. It is not known if VORANIGO is safe and effective in children under 12 years of age.

What are the possible side effects of VORANIGO?

VORANIGO may cause serious side effects, including:

Liver problems. Changes in liver function blood tests may happen during treatment with VORANIGO and can be serious. Your healthcare provider will do blood tests to check your liver function before and during treatment with VORANIGO. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems:

yellowing of your skin or the white part of your eyes (jaundice)

dark tea-colored urine

loss of appetite

pain on the upper right side of your stomach area

feeling very tired or weak

The most common side effects of VORANIGO include:

increased liver enzyme levels in the blood

lack of energy, tiredness

headache

COVID-19

muscle aches or stiffness

diarrhea

nausea

seizure

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VORANIGO if you have certain side effects.

VORANIGO may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of VORANIGO.

Before taking VORANIGO, tell your healthcare provider about all of your medical conditions, including if you:

have liver problems

have kidney problems or are on dialysis

smoke tobacco

are pregnant or plan to become pregnant. VORANIGO can harm your unborn baby

Females who are able to become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with VORANIGO

You should use effective nonhormonal birth control during treatment with VORANIGO and for 3 months after the last dose. VORANIGO may affect how hormonal contraceptives (birth control) work and cause them to not work well. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VORANIGO

Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VORANIGO

Males with female partners who are able to become pregnant:

You should use effective birth control during treatment with VORANIGO and for 3 months after the last dose

Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant during your treatment with VORANIGO

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if VORANIGO passes into breast milk. Do not breastfeed during treatment with VORANIGO and for 2 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VORANIGO may affect the way other medicines work, and other medicines may affect how VORANIGO works.

Please see Full Prescribing Information.

Close

This site uses cookies, and your privacy choice is important to us.

We use cookies to improve your experience, produce audience statistics, offer you services tailored to your interests, and provide features associated with social media. You can change your preferences at any time on the site.

Accept all cookies